The stock of Edwards Lifesciences Corp (EW) has seen a 1.62% increase in the past week, with a 6.14% gain in the past month, and a -3.34% decrease in the past quarter. The volatility ratio for the week is 1.95%, and the volatility levels for the past 30 days are at 2.13% for EW. The simple moving average for the past 20 days is 4.37% for EW’s stock, with a 15.50% simple moving average for the past 200 days.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio of 39.70x that is above its average ratio. Additionally, the 36-month beta value for EW is 1.11. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 7 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EW is 592.96M and currently, short sellers hold a 1.38% ratio of that float. The average trading volume of EW on July 01, 2024 was 2.77M shares.
EW) stock’s latest price update
Edwards Lifesciences Corp (NYSE: EW) has experienced a decline in its stock price by -1.04 compared to its previous closing price of 93.34. However, the company has seen a gain of 1.62% in its stock price over the last five trading days. youtube.com reported 2024-06-26 that The Investment Committee discuss their top stocks to watch for the second half.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Goldman repeating the rating for EW by listing it as a “Buy.” The predicted price for EW in the upcoming period, according to Goldman is $107 based on the research report published on May 30, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see EW reach a price target of $105, previously predicting the price at $98. The rating they have provided for EW stocks is “Buy” according to the report published on May 22nd, 2024.
EW Trading at 5.37% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.90% of loss for the given period.
Volatility was left at 2.13%, however, over the last 30 days, the volatility rate increased by 1.95%, as shares surge +5.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.88% upper at present.
During the last 5 trading sessions, EW rose by +1.62%, which changed the moving average for the period of 200-days by +25.90% in comparison to the 20-day moving average, which settled at $88.73. In addition, Edwards Lifesciences Corp saw 21.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Ullem Scott B., who sale 5,625 shares at the price of $87.51 back on Jun 20 ’24. After this action, Ullem Scott B. now owns 30,561 shares of Edwards Lifesciences Corp, valued at $492,258 using the latest closing price.
Lippis Daniel J., the CVP, JAPAC of Edwards Lifesciences Corp, sale 535 shares at $90.00 during a trade that took place back on Jun 20 ’24, which means that Lippis Daniel J. is holding 23,513 shares at $48,150 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.23. The total capital return value is set at 0.18. Equity return is now at value 21.59, with 15.38 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 0.85. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 56.96.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 8.97. The receivables turnover for the company is 7.01for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In conclusion, Edwards Lifesciences Corp (EW) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
